Stock analysts at StockNews.com assumed coverage on shares of OpGen (NASDAQ:OPGN – Get Free Report) in a report released on Sunday. The firm set a “sell” rating on the medical research company’s stock.
OpGen Trading Down 0.8 %
Shares of OPGN stock opened at $3.04 on Friday. OpGen has a 1 year low of $1.65 and a 1 year high of $38.40. The stock has a 50 day simple moving average of $2.86 and a 200 day simple moving average of $4.19.
OpGen (NASDAQ:OPGN – Get Free Report) last announced its quarterly earnings data on Monday, July 8th. The medical research company reported $0.21 EPS for the quarter. OpGen had a negative net margin of 997.34% and a negative return on equity of 1,827.76%. The business had revenue of $0.17 million during the quarter.
Institutional Inflows and Outflows
About OpGen
OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.
Further Reading
- Five stocks we like better than OpGen
- How to Calculate Stock Profit
- Survey: Top 175 Fittest Retirement Locations in America
- Ride Out The Recession With These Dividend KingsĀ
- Kimberly-Clark Stock Dips and a Buying Opportunity Emerges
- Technology Stocks Explained: Here’s What to Know About Tech
- Leading Gold Stock Shines With Q2 2024 Earnings Release
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.